Final Agenda

Lung and Other Aerodigestive Cancers Collaborative Group Virtual Meeting

Tuesday, June 30, 2020

10:00 a.m. - 6:00 p.m. EDT


Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center/Vanderbilt University Medical Center


James Herman, M.D., University of Pittsburgh

NCI Program Directors:

Lynn Sorbara, Ph.D., and Karl Krueger, Ph.D., National Cancer Institute

10:00 a.m. - 10:15 a.m. EDT

L01: Welcome and Introduction
Objective, Charge and Progress

  • Pierre Massion, M.D., Vanderbilt University
  • James Herman, M.D., University of Pittsburgh

Part I: 10:15 a.m. - 3:00 p.m. EDT

Site Updates/Progress/Future Study Plans

10:15 a.m. - 10:40 a.m. EDT L02: Optimizing DNA Methylation Detection for Early Lung Cancer
James Herman, M.D., University of Pittsburgh

10:40 a.m. - 10:45 a.m. EDT


10:45 a.m. - 11:10 a.m. EDT L03: The BU-UCLA Lung Cancer Biomarker Development Laboratory
Marc Lenburg, Ph.D., Boston University

11:10 a.m. - 11:15 a.m. EDT


11:15 a.m. - 11:40 a.m. EDT L04: 
Steve Dubinett, M.D., University of California, Los Angeles

11:40 a.m. - 11:45 a.m. EDT


11:45 a.m. - 12:10 p.m. EDT L05: Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer
Louise Showe, Ph.D., Wistar Institute

12:10 p.m. - 12:15 p.m. EDT


12:15 p.m. - 1:00 p.m. EDT

Lunch Break

1:00 p.m. - 1:25 p.m. EDT L06: Quantitative Imaging and Radiomics in the Early Detection of Lung Cancer
Matthew Schabath, Ph.D., Moffitt Cancer Center

1:25 p.m. - 1:30 p.m. EDT


1:30 p.m. - 1:55 p.m. EDT L07:
Harvey Pass, M.D., New York University/Langone Medical Center

1:55 p.m. - 2:00 p.m. EDT


2:00 p.m. - 2:25 p.m. EDT L08: Non-coding RNAs (ncRNAs) as Biomarkers for Early Detection of Non-Small Cell Lung Cancer in Sputum
Sanford Stass, M.D., University of Maryland

2:25 p.m. - 2:30 p.m. EDT


2:30 p.m. - 2:55 p.m. EDT L09:
Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center/Vanderbilt University Medical Center

2:55 p.m. - 3:00 p.m. EDT


3:00 p.m. - 3:15 p.m. EDT


Part II: 3:15 p.m. - 5:30 p.m. EDT

Discussion should focus on SWOT (Strengths, Weaknesses, Opportunities, and Threats)

  • What are the strengths of the EDRN and what can we do to further strengthen the Network;
  • Identify weaknesses and discuss the solutions (mitigation);
  • Discuss opportunities and highlight prioritized opportunities;
  • Discuss threats (competing interests/research) and mitigations.

Potential discussion topics in the context of SWOT:

  • How do we envision the collaboration with industry as a way of the future;
  • What can we do to focus more attention on including minorities in all biomarker testing and evaluation;
  • What are the ways that we can tap into and engage with many of the other CBRG and DCP programs, i.e., CIB, MCL, Tumor Atlas;
  • Discuss increasing the capacity for accrual for future studies;
  • How can we expand the role of the BRLs?
  • Discuss the potential of another collaborative group that is focused on common assays/technologies/biomarker validation?
  • Can the EDRN consider the integration of small clinical trials to move clinical utility forward?
  • How can we best bring junior investigators in our collaborative group;
  • How do we increase the number of collaborations between our lung collaborative group members?
  • Is EDRN ready to apply Universal Cancer Approach - multianalyte for Pan Cancer Detection?
5:30 p.m. - 6:00 p.m. EDT

Summary Write up
Drs. Pierre Massion, James Herman, Lynn Sorbara, and Karl Krueger will summarize the information for presentation at the general meeting tomorrow.

6:00 p.m. EDT


Version 5.1.0